Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial
In people with immune thrombocytopenia (ITP), the body produces destructive antibodies against platelets in the blood, which increases the risk of bruising, bleeding, hospitalization, death, fatigue, and an impaired quality ...